Trinity Biotech Plc (TRIB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$7.09

From 52W high−81.17%

Volume17146.00

Market cap$5.88M

P/E (TTM)—

P/S (TTM)0.1x

Div yield—

Key dataSep 18, 2026

Open

$7.09

From 52W high

−81.17%

Volume

17146.00

Market cap

$5.88M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−16.2x

P/E (TTM)

—

RSI (14)

28.9

MomentumView details →

1D Return

−0.48%

YTD Return

−69.49%

SummaryUpdated Dec 1, 2025

Trinity Biotech plc (NASDAQ:TRIB) is an Irish medical diagnostics company founded in 1992 and headquartered in Bray, Ireland. The company has been publicly traded since its IPO in October 1992. Trinity Biotech operates as a global manufacturer and distributor of medical diagnostic products, serving clinical laboratories and point-of-care testing markets across the Americas, Africa, Asia, and Europe. The company has undergone significant strategic transformation in recent years, pivoting from COVID-related testing revenues toward growth areas including HIV rapid testing, diabetes monitoring, and next-generation continuous glucose monitoring technology.

Ask drillr about Trinity Biotech Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−16.2x

EV/Sales

3.2x

P/S (TTM)

0.1x

P/B (TTM)

−0.1x

ProfitabilityView details →

Gross Margin

35.40%

Net Margin

−85.32%

EBITDA Margin

−19.53%

ROE (TTM)

51.99%

ROA (TTM)

−35.59%

Asset Turnover

0.42x

GrowthView details →

Revenue YoY

−28.74%

EPS YoY

−61.95%

FCF YoY

+60.98%

Revenue CAGR 3Y

−11.20%

EPS CAGR 3Y

−13.25%

EBITDA YoY

+49.33%

MomentumView details →

1D Return

−0.48%

YTD Return

−69.49%

1Y Return

−79.72%

RSI (14)

28.9

vs 50D SMA

−29.24%

vs 200D SMA

−60.86%

Capital & dividendView details →

Debt/Equity

−1.92x

Current Ratio

0.25x

Quick Ratio

0.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.23

EPS Surprise

25.81%

Beats (12Q)

5/12

Next Q EPS Est

−$8.40

Avg Surprise (4Q)

−22.00%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

43.86M

Net Income (TTM)

−37.43M

Op. CF (TTM)

−6.26M

Next earningsDec 10, 2026 →

Latest newsMore news →

Jordi Romero joined Trinity Biotech as Head of Commercial Operations – Europe.23d ago

Trinity Biotech plc announced a change in the ratio of its American depositary shares from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares.60d ago

Similar companies

bioAffinity Technologies, Inc.BIAF Intelligent Bio Solutions Inc.INBS BioNexus Gene Lab Corp.BGLC ENDRA Life Sciences Inc.NDRA iSpecimen Inc.ISPC Advanced Biomed Inc. Common StockADVB Find similar companies →

Latest newsMore news →

Jordi Romero joined Trinity Biotech as Head of Commercial Operations – Europe.23d ago Trinity Biotech plc announced a change in the ratio of its American depositary shares from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares.60d ago